Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dronabinol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 10/20 | 1.00 |
| ▸ | CNR2 | P34972 | 16/20 | 1.00 |
| ▸ | ABHD12 | Q8N2K0 | 3/20 | 1.00 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 1.00 |
| ▸ | FAAH | O00519 | 2/20 | 1.00 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 1.00 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | LDHA | P00338 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 1/20 | 1.00 |
| ▸ | GPR18 | Q14330 | 1/20 | 1.00 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.86 |
| ▸ | HTR1A | P08908 | 1/20 | 0.86 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.86 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.86 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.86 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dronabinol SCHEMBL29390424 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL13394311 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL29349828 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL1227386 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL13214137 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL24702729 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL3686519 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL4609 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL22705549 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL29410178 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029718-B2 | Process for production of essentially pure delta-9-tetrahydrocannabinol | CCT SCIENCES, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029718-B2 | Process for production of essentially pure delta-9-tetrahydrocannabinol | CCT SCIENCES, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-11911401-B2 | Tryptamine compositions for enhancing neurite outgrowth | TURTLE BEAR HOLDINGS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230398073-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS | RHODES TECHNOLOGIES (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230398073-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS | RHODES TECHNOLOGIES (US) | 2023-12-14 | — | — | US | disclosed |
| US-11786463-B2 | Pharmaceutical compositions for the treatment of ophthalmic conditions | RHODES TECHNOLOGIES (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786463-B2 | Pharmaceutical compositions for the treatment of ophthalmic conditions | RHODES TECHNOLOGIES (US) | 2023-10-17 | — | — | US | disclosed |
| US-11753390-B2 | Δ-8-tetrahydrocannabinol from cannabidiol extracted from hemp | CCT SCIENCES, LLC | 2023-09-12 | — | — | US | disclosed |
| US-11753390-B2 | Δ-8-tetrahydrocannabinol from cannabidiol extracted from hemp | CCT SCIENCES, LLC | 2023-09-12 | — | — | US | disclosed |
| US-20230233635-A1 | CANNABINOID COMPOSITIONS AND DOSAGE FORMS FOR INTRANASAL OR INHALATIONAL DELIVERY | RHODES TECHNOLOGIES (US) | 2023-07-27 | — | — | US | disclosed |
| US-9278083-B2 | Methods for purifying trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol | SVC PHARMA LP (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150126596-A1 | METHODS FOR PURIFYING TRANS-(-)-Delta9-TETRAHYDROCANNABINOL AND TRANS-(+)-Delta9-TETRAHYDROCANNABINOL | EURO-CELTIQUE S.A. (LU) | 2015-05-07 | — | — | US | disclosed |
| US-8937097-B2 | Methods for purifying trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol | PURDUE PHARMA L.P. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20130171259-A1 | METHODS FOR PURIFYING TRANS-(-)-DELTA9-TETRAHYDROCANNABINOL AND TRANS-(+)-DELTA9-TETRAHYDROCANNABINOL | PURDUE PHARMA L.P. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8383842-B2 | Methods for purifying trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol | PURDUE PHARMA L.P. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20090298930-A1 | Methods For Purifying Trans-(-) Delta9-Tetrahydrocannabinol And Trans-(+)-Delta9-Tetrahydrocannabinol | EURO-CELTIQUE S.A. (LU) | 2009-12-03 | — | — | US | disclosed |
| US-20080176885-A1 | Improved Pharmacokinetics; side effects reduction; codrugs are covalently bound by a linker that is capable of cleavage in the body; analgesics | UNIVERSITY OF KENTUCKY (US) | 2008-07-24 | — | — | US | disclosed |
| US-20070072939-A1 | Cannabinoid active pharmaceutical ingredient for improved dosage forms | EURO-CELTIQUE, S.A. | 2007-03-29 | — | — | US | disclosed |
| US-4243674-A | HYPOTENSIVE AGENTS; ANALGESICS; ANTISECRETORY AGENTS; ANTIBODY INHIBITORS, AND TRANQUILIZERS | PFIZER INC. (US) | 1981-01-06 | — | — | US | disclosed |
| US-4143139-A | ANALGESICS, HYPOTENSIVES, IMMUNOSUPPRESSANTS, TRANQUILIZERS, ANTISECRETORY, ANTI-ANXIETY | PFIZER INC. (US) | 1979-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753390-B2 | Δ-8-tetrahydrocannabinol from cannabidiol extracted from hemp | UGT8, CNR2, CYP8B1 | CNR1 4/4885CNR2 2/4885ABHD12 1199/4885 |
| US-20150126596-A1 | METHODS FOR PURIFYING TRANS-(-)-Delta9-TETRAHYDROCANNABINOL AND TRANS-(+)-Delta9-TETRAHYDROCANNABINOL | CNR2, CNR1, OPRD1 | CNR1 2/4885CNR2 1/4885ABHD12 868/4885 |
| US-20090298930-A1 | Methods For Purifying Trans-(-) Delta9-Tetrahydrocannabinol And Trans-(+)-Delta9-Tetrahydrocannabinol | CNR2, OPRD1, CNR1 | CNR1 3/4885CNR2 1/4885ABHD12 948/4885 |
| US-20070072939-A1 | Cannabinoid active pharmaceutical ingredient for improved dosage forms | CNR2, CNR1, OPRD1 | CNR1 2/4885CNR2 1/4885ABHD12 1585/4885 |
| US-20080176885-A1 | Improved Pharmacokinetics; side effects reduction; codrugs are covalently bound by a linker that is capable of cleavage in the body; analgesics | OPRK1, CNR1, CNR2 | CNR1 2/4885CNR2 3/4885ABHD12 2468/4885 |
| US-20230233635-A1 | CANNABINOID COMPOSITIONS AND DOSAGE FORMS FOR INTRANASAL OR INHALATIONAL DELIVERY | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885ABHD12 862/4885 |
| US-20230398073-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885ABHD12 519/4885 |
| US-20130171259-A1 | METHODS FOR PURIFYING TRANS-(-)-DELTA9-TETRAHYDROCANNABINOL AND TRANS-(+)-DELTA9-TETRAHYDROCANNABINOL | CNR2, CNR1, OPRD1 | CNR1 2/4885CNR2 1/4885ABHD12 848/4885 |
| US-11911401-B2 | Tryptamine compositions for enhancing neurite outgrowth | HTR1B, HTR6, BDNF | CNR1 28/4885CNR2 24/4885ABHD12 3122/4885 |
| US-12029718-B2 | Process for production of essentially pure delta-9-tetrahydrocannabinol | CNR2, CNR1, DAGLA | CNR1 2/4885CNR2 1/4885ABHD12 1915/4885 |
| US-11786463-B2 | Pharmaceutical compositions for the treatment of ophthalmic conditions | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885ABHD12 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.